• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by GlucoTrack Inc.

    9/10/24 1:32:03 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care
    Get the next $GCTK alert in real time by email
    SC 13G 1 ea0214129-13gsycoff_gluco.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. __)

     

    GLUCOTRACK, INC.

    (Name of Issuer)

     

    COMMON STOCK

    (Title of Class of Securities)

     

    45824Q507

    (CUSIP Number)

     

    September 5, 2024

    (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following page(s)

     

     

     

    Page 1 of 5 Pages

     

     

    CUSIP No. 45824Q507  13G  Page 2 of 5 Pages

     

    1. NAMES OF REPORTING PERSON
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Drew Sycoff
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
    (a) ☐
    (b) ☐
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION - USA
    5. SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON – 321,264 Shares (1) (2) (3)
    6. SHARED VOTING POWER - None
    7. SOLE DISPOSITIVE POWER – 321,264 Shares (1) (2) (3)
    8. SHARED DISPOSITIVE POWER – None
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON – 321,264 Shares (1) (2) (3)
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☒
    The aggregate amount in Row 9 represents the maximum amount of shares that Drew Sycoff can beneficially control under a contractually stipulated 4.99% ownership restriction. The full exercise of Drew Sycoff’s securities would exceed this restriction.
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    5.864% (1) (2) (3)
    12. TYPE OF REPORTING PERSON
    IN

     

    (1)Based on 5,478,436 shares outstanding as of August 19, 2024 as reported in the Definitive Schedule 14A filed by the Issuer on August 19, 2024.

     

    (2)Does not include 23,299 shares of common stock owned directly by Andrew Garrett, Inc. of which the Reporting Person is the Chief Executive Officer. The Reporting Person disclaims beneficial ownership of the securities owned by Andrew Garrett, Inc. except to the extent of his pecuniary interests therein.

     

    (3)Does not include 515,187 shares of common stock owned directly by Alma Diversified Holdings LLC, an entity owned by the wife of the Reporting Person. Mr. Sycott disclaims beneficial ownership of the securities owned by Alma Diversified Holdings LLC except to the extent of his pecuniary interests therein.

     

     

     

     

    CUSIP No. 45824Q507  13G  Page 3 of 5 Pages

     

    ITEM 1 (a) NAME OF ISSUER: GlucoTrack, Inc.

     

    ITEM 1 (b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

     

    301 Rt 17 North, Suite 800, Rutherford, NJ 07070

     

    ITEM 2 (a) NAME OF PERSON FILING: Drew Sycoff

     

    ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

    1294 Albany Post Rd., Gardiner, NY 12525

     

    ITEM 2 (c) CITIZENSHIP: USA

     

    ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Shares, $0.001 par value per share, and Common Stock Purchase Warrants

     

    ITEM 2 (e) CUSIP NUMBER: 45824Q507

     

    ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable

     

    ITEM 4 OWNERSHIP

     

    (a) AMOUNT BENEFICIALLY OWNED: 321,264 Shares (1) (2) (3)

     

    (b) PERCENT OF CLASS: 5.864% (1) (2) (3)

     

    (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

     

    (i) SOLE POWER TO VOTE OR DIRECT THE VOTE

     

    321,264 Shares (1) (2) (3)

     

    (ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

     

    0 Shares

     

    (iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    321,264 Shares (1) (2) (3)

     

    (iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    0 Shares

     

     

     

     

    CUSIP No. 45824Q507  13G  Page 4 of 5 Pages

     

    ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Not applicable

     

    ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable

     

    ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    Not applicable

     

    ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

     

    Not applicable

     

    ITEM 9 NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable

     

     

     

     

    CUSIP No. 45824Q507  13G  Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      September 10, 2024
      (Date)
       
      /s/ Drew Sycoff
      (Signature)
       
      Drew Sycoff
      (Name/Title)

     

     

     

     

    Get the next $GCTK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GCTK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GCTK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption (IDE) approval for novel CBGM technology from FDA expected in Q4 2025 Rutherford, NJ, May 14, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2025. "I am pleased with the progress we made during the quarter a

      5/14/25 5:10:00 PM ET
      $GCTK
      Medical/Dental Instruments
      Health Care
    • Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor

      RUTHERFORD, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced it has received ethical approval from the St. Vincent's Hospital Melbourne Human Research Ethics Committee (HREC) for its long-term clinical study of the Company's continuous blood glucose monitor ("CBGM") in participants with type 1 and type 2 diabetes. The prospective, single arm, multi-center study will enroll up to 30 participants with type 1 and type 2 diabetes mellitus requiring glucose monitoring and intensive insulin therap

      5/13/25 8:01:00 AM ET
      $GCTK
      Medical/Dental Instruments
      Health Care
    • Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas

      RUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery system that will enable optimal glucose control without patient intervention. FORGETDIABETES is funded by the European Union's Horizon 2020 research and innovation program, a multi-year funding program with €75 Billion to support initiatives ranging from basic research to innovative product develop

      4/16/25 8:00:00 AM ET
      $GCTK
      Medical/Dental Instruments
      Health Care

    $GCTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sycoff Drew bought $230,000 worth of shares (182,540 units at $1.26), increasing direct ownership by 7% to 2,951,258 units (SEC Form 4)

      4 - GlucoTrack, Inc. (0001506983) (Issuer)

      4/24/24 6:31:49 PM ET
      $GCTK
      Medical/Dental Instruments
      Health Care

    $GCTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner John A. Ballantyne Revocable Living Trust Dated 08/01/2017 acquired $4,093,116 worth of shares (132,036 units at $31.00) and converted options into 2,560,553 shares, increasing direct ownership by 5,279% to 2,743,591 units (SEC Form 4)

      4 - Glucotrack, Inc. (0001506983) (Issuer)

      3/31/25 9:20:04 AM ET
      $GCTK
      Medical/Dental Instruments
      Health Care
    • Director Ballantyne John was granted 4,126 shares, acquired $4,093,116 worth of shares (132,036 units at $31.00) and converted options into 2,560,553 shares (SEC Form 4)

      4 - Glucotrack, Inc. (0001506983) (Issuer)

      3/31/25 8:54:53 AM ET
      $GCTK
      Medical/Dental Instruments
      Health Care
    • Director Malave Luis was granted 3,199 shares, converted options into 6,886 shares and converted options into 133,532 shares (SEC Form 4)

      4 - Glucotrack, Inc. (0001506983) (Issuer)

      3/31/25 8:17:33 AM ET
      $GCTK
      Medical/Dental Instruments
      Health Care

    $GCTK
    SEC Filings

    See more
    • SEC Form 10-Q filed by GlucoTrack Inc.

      10-Q - Glucotrack, Inc. (0001506983) (Filer)

      5/14/25 5:20:28 PM ET
      $GCTK
      Medical/Dental Instruments
      Health Care
    • GlucoTrack Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Glucotrack, Inc. (0001506983) (Filer)

      5/14/25 5:15:22 PM ET
      $GCTK
      Medical/Dental Instruments
      Health Care
    • GlucoTrack Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Glucotrack, Inc. (0001506983) (Filer)

      5/13/25 8:45:47 AM ET
      $GCTK
      Medical/Dental Instruments
      Health Care

    $GCTK
    Leadership Updates

    Live Leadership Updates

    See more
    • Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member

      RUTHERFORD, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Guillermo Umpierrez, MD, CDCES, FACE, MACP, has been named as Glucotrack's new Medical Advisory Board member, effective immediately. "With his invaluable experience in diabetes care and his dedication to improving the lives of people with diabetes, Dr. Umpierrez brings exceptional clinical and research expertise that will be instrumental as we advance our novel Continuous Blood Glucose Monitoring (CBGM) technology through clinical development," said Paul V.

      2/26/25 8:01:00 AM ET
      $GCTK
      Medical/Dental Instruments
      Health Care
    • Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer

      RUTHERFORD, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that Peter C. Wulff has been named Chief Financial Officer, effective immediately. Mr. Wulff has over 35 years of financial management experience in both public and privately held companies in the emerging growth life sciences sector. He has a strong track record of successfully raising capital through a variety of mechanisms including public and private equity offerings, debt financing, and strategic business transactions. Mr

      1/29/25 9:00:07 AM ET
      $GCTK
      Medical/Dental Instruments
      Health Care
    • Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs

      RUTHERFORD, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Ted Williams has been named Vice President of Regulatory Affairs, effective immediately. Mr. Williams has nearly 25 years of experience and a proven track record of successful management of Regulatory Affairs and Quality Assurance for highly complex Class III medical devices including active, long term implantable continuous glucose monitors ("CGM"), drug/device combination products, in-dwelling catheter based endovascula

      1/15/25 8:01:00 AM ET
      $GCTK
      Medical/Dental Instruments
      Health Care

    $GCTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by GlucoTrack Inc.

      SC 13G - Glucotrack, Inc. (0001506983) (Subject)

      9/10/24 1:32:03 PM ET
      $GCTK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by GlucoTrack Inc.

      SC 13G - GlucoTrack, Inc. (0001506983) (Subject)

      1/3/24 1:54:20 PM ET
      $GCTK
      Medical/Dental Instruments
      Health Care

    $GCTK
    Financials

    Live finance-specific insights

    See more
    • GLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT

      1-for-5 reverse stock split to become effective as of the opening of trading onMay 20, 2024 Rutherford, NJ, May 15, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-5 reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock (the "Common Stock"), effective with the opening of trading on Monday, May 20, 2024. Glucotrack's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "GCTK". The new CUSIP number

      5/15/24 4:15:00 PM ET
      $GCTK
      Medical/Dental Instruments
      Health Care